We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
DOVATO (ViiV Healthcare Pty Ltd)
Product name
DOVATO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
170 working days (255)
Active ingredients
dolutegravir sodium; lamivudine
Registration type
EOI
Indication
DOVATO (film coated tablet) is now also indicated to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to the integrase inhibitor class or lamivudine (see section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials).